The Latest Breaking News from GH Research

3 Biotech Stocks Wall Street Analysts Predict Will More Than Double

What makes analysts so bullish about these three names from the sector?

Barchart · Nov 20, 2025

Depression-Focused GH Research Shares Could See Significant Upside: Analyst

Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company’s lead drug candidate, GH-001, which had demonstrated impressive efficacy in Phase 2 versus competition.

Benzinga · Oct 13, 2025

GH Research Shares Q2 2022 Financial Results & Business Updates

GH Research PLC (NASDAQ: GHRS), the clinical-stage biopharma company dedicated to transforming the treatment of psychiatric and neurological disorders through 5-MeO-DMT production, provided a financial and business update for the quarter ended June 30, 2022.

Benzinga · Aug 23, 2022

Intelgenx Technologies, Field Trip Health Among Top Psychedelic Movers Of Today

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 4.78% at $19.73 LOSERS:

Benzinga · Apr 6, 2022

Psychedelic Stock Gainers And Losers From March 7, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 1.49% at $15.71 LOSERS:

Benzinga · Mar 7, 2022

Small Pharma, GH Research Among Top Psychedelic Movers Of Today

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.99% at $0.24

Benzinga · Feb 23, 2022

Psychedelic Stock Gainers And Losers From January 21, 2022

GAINERS: GH Research (NASDAQ:GHRS) shares closed up 1.18% at $17.19 LOSERS:

Benzinga · Jan 21, 2022